Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.drup.2016.09.002 http://scihub22266oqcxt.onion/10.1016/j.drup.2016.09.002 C5140036!5140036!27912842     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drug+Resist+Updat 2016 ; 29 (ä): 30-46 Nephropedia Template TP {{tp|p=27912842|t=2016. The rapid spread of carbapenem-resistant Enterobacteriaceae |pdf=|usr=}}{{27912842}} gab.com Text The rapid spread of carbapenem-resistant Enterobacteriaceae JO: Drug Resist Updat http://www.kidney.de/pget.php?&tw=1&pmid=27912842 #FOAvip Carbapenems, our one-time silver bullet for multidrug resistant bacterial infections, are now threatened by widespread dissemination of carbapenem-resistant Enterobacteriaceae (CRE). Successful expansion of Enterobacteriaceae clonal groups and frequent horizontal gene transfer of carbapenemase expressing plasmids are causing increasing carbapenem resistance. Recent advances in genetic and phenotypic detection facilitate global surveillance of CRE diversity and prevalence. In particular, whole genome sequencing enabled efficient tracking, annotation, and study of genetic elements colocalized with carbapenemase genes on chromosomes and on plasmids. Improved characterization helps detail the co-occurrence of other antibiotic resistance genes in CRE isolates and helps identify pan-drug resistance mechanisms. The novel ?-lactamase inhibitor, avibactam, combined with ceftazidime or aztreonam, is a promising CRE treatment compared to current colistin or tigecycline regimens. To halt increasing CRE-associated morbidity and mortality, we must continue quality, cooperative monitoring and urgently investigate novel treatments. Twit Text FOAVip The rapid spread of carbapenem-resistant Enterobacteriaceae ????Drug Resist Updat http://www.kidney.de/pget.php?&tw=1&pmid=27912842 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27912842 #FOAvip English Wikipedia <ref>{{Cite pmid|27912842}}</ref> The rapid spread of carbapenem-resistant Enterobacteriaceae #MMPMID27912842 Potter RF; D?Souza AW; Dantas G Drug Resist Updat 2016[Nov]; 29 (ä): 30-46 PMID27912842show ga Carbapenems, our one-time silver bullet for multidrug resistant bacterial infections, are now threatened by widespread dissemination of carbapenem-resistant Enterobacteriaceae (CRE). Successful expansion of Enterobacteriaceae clonal groups and frequent horizontal gene transfer of carbapenemase expressing plasmids are causing increasing carbapenem resistance. Recent advances in genetic and phenotypic detection facilitate global surveillance of CRE diversity and prevalence. In particular, whole genome sequencing enabled efficient tracking, annotation, and study of genetic elements colocalized with carbapenemase genes on chromosomes and on plasmids. Improved characterization helps detail the co-occurrence of other antibiotic resistance genes in CRE isolates and helps identify pan-drug resistance mechanisms. The novel ?-lactamase inhibitor, avibactam, combined with ceftazidime or aztreonam, is a promising CRE treatment compared to current colistin or tigecycline regimens. To halt increasing CRE-associated morbidity and mortality, we must continue quality, cooperative monitoring and urgently investigate novel treatments. äThe rapid spread of carbapenem-resistant Enterobacteriaceae (epmc).pdf DeepDyve Pubget Overpricing